PE20150752A1 - Proteinas de fusion de interleuquina-2 y usos de las mismas - Google Patents

Proteinas de fusion de interleuquina-2 y usos de las mismas

Info

Publication number
PE20150752A1
PE20150752A1 PE2014002251A PE2014002251A PE20150752A1 PE 20150752 A1 PE20150752 A1 PE 20150752A1 PE 2014002251 A PE2014002251 A PE 2014002251A PE 2014002251 A PE2014002251 A PE 2014002251A PE 20150752 A1 PE20150752 A1 PE 20150752A1
Authority
PE
Peru
Prior art keywords
fusion proteins
interleuquin
methods
present
relates
Prior art date
Application number
PE2014002251A
Other languages
English (en)
Inventor
Ralf Hosse
Christian Klein
Ekkehard Moessner
Laurence Bernard Peterson
Pablo Umana
Linda Wicker
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48948417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150752(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of PE20150752A1 publication Critical patent/PE20150752A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere de manera general a proteinas de fusion de inmunoglobulinas e interleuquina-2 (IL-2). Ademas, la presente invencion se refiere a polinucleotidos codificantes de dichas proteinas de fusion, y a vectores y celulas huesped que comprenden dichos polinucleotidos. La invencion se refiere ademas a metodos para producir las proteinas de fusion de la invencion, y a metodos de utilizacion de los mismos en el tratamiento o profilaxis de enfermedades autoinmunologicas.
PE2014002251A 2012-08-10 2013-08-07 Proteinas de fusion de interleuquina-2 y usos de las mismas PE20150752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261681676P 2012-08-10 2012-08-10

Publications (1)

Publication Number Publication Date
PE20150752A1 true PE20150752A1 (es) 2015-05-15

Family

ID=48948417

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002251A PE20150752A1 (es) 2012-08-10 2013-08-07 Proteinas de fusion de interleuquina-2 y usos de las mismas

Country Status (22)

Country Link
US (4) US20140044675A1 (es)
EP (1) EP2882458B1 (es)
JP (1) JP6526561B2 (es)
KR (1) KR20150041628A (es)
CN (2) CN111635460A (es)
AR (1) AR092089A1 (es)
AU (1) AU2013301562B2 (es)
BR (1) BR112015002765A2 (es)
CA (1) CA2873291A1 (es)
CL (1) CL2014003322A1 (es)
CO (1) CO7121348A2 (es)
CR (1) CR20140532A (es)
EA (1) EA201500206A1 (es)
HK (1) HK1208827A1 (es)
IL (1) IL236933A0 (es)
MA (1) MA37894B1 (es)
MX (1) MX2015001749A (es)
PE (1) PE20150752A1 (es)
PH (1) PH12014502767A1 (es)
SG (1) SG11201407579QA (es)
TW (1) TW201420607A (es)
WO (1) WO2014023752A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2673294B1 (en) 2011-02-10 2016-04-27 Roche Glycart AG Mutant interleukin-2 polypeptides
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
MX370283B (es) 2014-02-06 2019-12-09 Hoffmann La Roche Proteinas de fusion de interleucina-2 y usos de las mismas.
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA40721A (fr) * 2014-08-06 2017-06-13 The Univ Of Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
PL3482766T3 (pl) * 2014-08-11 2020-11-16 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
CN115925939A (zh) * 2015-08-06 2023-04-07 新加坡科技研究局 IL2Rβ/通用γ链抗体
AU2016362777B2 (en) 2015-12-04 2020-01-30 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
CA3019005A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
DK3558339T3 (da) 2016-12-22 2024-02-26 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
CN111010875B (zh) 2017-03-15 2024-04-05 库尔生物制药有限公司 用于调节免疫应答的方法
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3743438A4 (en) * 2018-01-24 2022-02-23 Beijing Percans Oncology Co. Ltd. CYTOKI FUSION PROTEINS
EP3752178A1 (en) 2018-02-16 2020-12-23 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
MX2020009975A (es) 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
WO2020127277A1 (en) 2018-12-18 2020-06-25 Robert Koch-Institut A peptide-loaded mhc-i presenting cell and an il-2 with extended half-life for amplifying a cellular cytotoxic immune response
CA3166887A1 (en) 2020-03-06 2021-09-10 Gilbert BENSIMON Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
EP4149534A2 (en) 2020-05-12 2023-03-22 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CA3177843A1 (en) 2020-05-13 2021-11-18 John Thomas MULLIGAN Compositions of protein complexes and methods of use thereof
CN113912734A (zh) * 2020-07-08 2022-01-11 南京师范大学 融合多肽及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN112724259B (zh) * 2020-11-16 2022-12-20 天津林达生物科技有限公司 人血清白蛋白与白介素2的融合蛋白及其用途
CN113248610B (zh) * 2021-05-14 2022-08-16 厦门柏慈生物科技有限公司 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途
TW202402784A (zh) * 2022-07-06 2024-01-16 中國商科望（上海）生物醫藥科技有限公司 Il2突變蛋白及其用途
CN117003852A (zh) * 2022-07-07 2023-11-07 北京大学 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
KR20240055222A (ko) * 2022-10-19 2024-04-29 주식회사 에이프릴바이오 인터루킨-2 변이 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
CN117986383A (zh) * 2022-11-02 2024-05-07 北京昌平实验室 融合蛋白及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR7801185A (pt) 1977-04-18 1978-11-28 Hitachi Metals Ltd Ornato adaptado para ser fixado por pelo menos um ima permanente
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60502136A (ja) * 1983-08-10 1985-12-12 アムジエン　インコーポレイテツド 微生物によるインタ−ル−キン２の形質発現
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
EP1060194A1 (en) * 1998-02-25 2000-12-20 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
BR0014480A (pt) 1999-10-04 2002-06-11 Medicago Inc Método para regular a transcrição de genes estranhos
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
JP2007527242A (ja) 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
NZ550217A (en) 2004-03-31 2009-11-27 Genentech Inc Humanized anti-TGF-beta antibodies
EP2374817B1 (en) 2004-04-13 2017-09-06 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2587572A1 (en) 2004-11-24 2006-06-01 Schering Corporation Dap-10 and uses thereof
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
AU2008278803A1 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to KDR and uses thereof - 035
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
JP5766124B2 (ja) 2009-01-21 2015-08-19 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
MA34519B1 (fr) 2010-08-13 2013-09-02 Roche Glycart Ag Anticorps anti-fap et procédés d'utilisation
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
EP2673294B1 (en) 2011-02-10 2016-04-27 Roche Glycart AG Mutant interleukin-2 polypeptides
KR102220006B1 (ko) 2011-03-11 2021-02-24 아시스땅스 퍼블리끄-오삐또 드 빠리 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ­２ 의 용도
SG193554A1 (en) 2011-03-29 2013-11-29 Roche Glycart Ag Antibody fc variants
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
MX370283B (es) 2014-02-06 2019-12-09 Hoffmann La Roche Proteinas de fusion de interleucina-2 y usos de las mismas.
MA40721A (fr) 2014-08-06 2017-06-13 The Univ Of Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
EP2882458B1 (en) 2018-07-11
EP2882458A1 (en) 2015-06-17
TW201420607A (zh) 2014-06-01
AU2013301562A1 (en) 2014-11-20
US20180009868A1 (en) 2018-01-11
AR092089A1 (es) 2015-03-25
JP2015530984A (ja) 2015-10-29
CN111635460A (zh) 2020-09-08
US11365232B2 (en) 2022-06-21
PH12014502767A1 (en) 2015-02-09
US20160090407A1 (en) 2016-03-31
EA201500206A1 (ru) 2016-04-29
MX2015001749A (es) 2015-06-05
CA2873291A1 (en) 2014-02-13
CO7121348A2 (es) 2014-11-20
CL2014003322A1 (es) 2015-02-13
CN104507504A (zh) 2015-04-08
US20200172591A1 (en) 2020-06-04
HK1208827A1 (en) 2016-03-18
SG11201407579QA (en) 2014-12-30
BR112015002765A2 (pt) 2018-03-13
WO2014023752A1 (en) 2014-02-13
KR20150041628A (ko) 2015-04-16
MA37894A1 (fr) 2018-07-31
US20140044675A1 (en) 2014-02-13
MA37894B1 (fr) 2020-01-31
AU2013301562B2 (en) 2017-04-06
CR20140532A (es) 2015-01-12
IL236933A0 (en) 2015-03-31
JP6526561B2 (ja) 2019-06-05
US10562949B2 (en) 2020-02-18

Similar Documents

Publication Publication Date Title
PE20150752A1 (es) Proteinas de fusion de interleuquina-2 y usos de las mismas
PE20150645A1 (es) Proteinas de fusion de interleuquina 10 y usos de las mismas
CR20160333A (es) Proteinas de fusión de interleucina-2 y usos de las mismas
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
AR113177A2 (es) Polipéptidos que tienen actividad de lisozima y polinucleótidos que los codifican
AR120543A2 (es) Moléculas biespecíficas de células t activadas por proteasas
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
CO2017013710A2 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t.
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
AR122864A2 (es) Variantes de lipasa y polinucleótidos que las codifican
PE20151410A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
CR20170203A (es) Moleculas de unión a antígeno biespecíficas activadoras de células t
CO2018002196A2 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
PE20190564A1 (es) Variantes de xilanasa y polinucleotidos que las codifican
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
BR112015022208A8 (pt) proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
AR073088A1 (es) Anticuerpos anti-il-13 obtenidos mediante ingenieria composiciones metodos y usos
BR112017013956A2 (pt) proteínas de fusão de citocinas
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
CR20150544A (es) Proteinas específicas para el baff y para la b7rp1 y sus usos
PE20151925A1 (es) Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer

Legal Events

Date Code Title Description
FD Application declared void or lapsed